Neurotech Insights
April 30, 2008
Inside This Issue: Cognitive Impairment Associated with Schizophrenia (CIAS)
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Paving the way for CIAS Treatments
Featured Company: Synosia
Subscribe now to access hundreds of articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Flood of data from April annual neurology meetings
Elan (ELN) reached a 52 week high this month despite suspending a trial on one of their leads for Alzheimer’s (ACC-001) due to an adverse effect in one patient (see story, page 7). The company reported higher than expected use and a better safety record for their multiple sclerosis treatment, Tysabri at the annual meeting of the American Academy of Neurology (AAN). At the end of the first quarter, the companies said there was a 25% rise in prescriptions compared to the last quarter of 2007. More than 36,700 patients have now been treated with the drug, and there have been no new cases of progressive multifocal leukoencephalopathy (PML)...
Positive developments in treatments for negative symptoms of schizophrenia
In 1908, Swiss psychiatrist Paul Eugen Bleuler coined the term schizophrenia, meaning split mind, to describe a mental illness characterized by loss of contact with reality, delusions, auditory hallucinations, and flattened affect. Before 1908, schizophrenia was known as dementia praecox, or early-onset dementia, a term that was introduced in 1891 by the German psychiatrist Arnold Pick. Pick described young patients (praecox) with a rapid cognitive disintegration accompanied by psychotic symptoms. He thought these patients had early onset dementia ...
Synosia: Imaging its way to new treatments
Synosia Therapeutics was a nascent neuropharmaceutical company when CEO Dr. Ian Massey joined in 2006 from Roche Palo Alto where he was head of research and preclinical development. When he came on board he brought with him a series of compounds from Roche that he thought Roche could have been pursuing more aggressively. "I saw an opportunity in a small dynamic organization to capitalize on the clinical data, use proof of mechanism approaches and apply these to important compounds that had been deprioritized at Roche," states Massey...
Companies Covered In This Issue Include: Alseres Pharmaceuticals, Arena Pharmaceuticals, Baxter International, BioMS, CoMentis, Coaxia, Constellation Pharmaceuticals, Elan, Eisai, Envivo Pharmaceuticals, Impax Laboratories, Jazz Pharmaceuticals, J&J, Knopp Neurosciences, Medivation, Neurometrix, Novartis, Pluristem Therapeutics, Pipex Pharmaceuticals, Somaxon, Safinova-Aventis, St. Jude Medical Somaxon Pharmaceuticals, Teva Pharmaceuticals, Victhom Human Bionics, Vitreoretinal Technologies, and Vivus, Apex Bioventures, BrainCells Inc., BrainLab, Cambria Pharmaceuticals, Capnia, Concert Pharmaceuticals, Constellation Pharmaceuticals, D-Pharm, Dynogen, Micrus Endovascular, Moleac, Neurogen, Pozen, GlaxoSmithKline, Philips Electronics, Satoris, and Targeted Genetics, Nuon Therapeutics, Allon Therapeutics, AstraZeneca, Avera Pharmaceuticals, Brainsway, Cephalon, Epix Pharmaceuticals, Memory Pharma, Merck, Pfizer, Sanofi-Aventis, Synosia, Targacept, Wyeth, Xytis and more.
Subscribe Now:
Neurotech Insights subscription includes:
- Monthly newsletter containing the latest product development news, deals, and feature stories
- Access to a searchable web archive of articles, companies and investors (NEW!)
Contact us for an enterprise license, academic discounts and NIO member discounts at (415)229-3225.
|
|
